Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: Evidence and implications for the addictions field

Addiction

Volumn 106, Issue 2, 2011, Pages 283-293

  Ambermoon, Polly ^a   Carter, Adrian ^a,b   Hall, Wayne D ^a,c   Dissanayaka, Nadeeka N W ^a,d   O'Sullivan, John D ^c,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Behavioural addictions; Dopamine agonists; Gambling; Hypersexuality; Impulse control disorders; Parkinson's disease; Substance abuse

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADDICTION; ADULT; AGED; BINGE EATING DISORDER; EPIDEMIOLOGY; FEMALE; HUMAN; IMPULSE CONTROL DISORDER; MALE; MIDDLE AGED; PARKINSON DISEASE; PSYCHOSEXUAL DISORDER; REVIEW;

ADULT; AGED; BEHAVIOR, ADDICTIVE; BINGE-EATING DISORDER; DOPAMINE AGONISTS; EPIDEMIOLOGIC FACTORS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMPULSE CONTROL DISORDERS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SUBSTANCE-RELATED DISORDERS;

EID: 78650822316     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2010.03218.x     Document Type: Review

References (62)

1. Przedborski S. Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat Disord 2005; 11: S3-7.
2. Nissenbaum H., Quinn N. P., Brown R. G., Toone B., Gotham A. M., Marsden C. D. Mood swings associated with the on-off phenomenon in Parkinson's disease. Psychol Med 1987; 17: 899-904.
3. Witjas T., Kaphan E., Azulay J. P., Blin O., Ceccaldi M., Pouget J. et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408-13.
4. Simuni T., Lyons K. E., Pahwa R., Hauser R. A., Comella C., Elmer L. et al. Treatment of early Parkinson's disease. Part 2. Eur Neurol 2009; 61: 206-15.
5. Hayes M. W., Fung V. S., Kimber T. E., O'Sullivan J. D. Current concepts in the management of Parkinson disease. Med J Aust 2010; 192: 144-9.
6. Shapiro M. A., Chang Y. L., Okun M. S., Rodriguez R. L., Skidmore F. M., Fernandez H. H. Is Pathological Gambling in Parkinson's Disease a Compulsive or Impulsive Disorder? Paper presented at: 20th Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinsons Disease and Other Movement Disorders. Chicago, IL: Wiley-Liss; 2006.
7. Lawrence A. D., Evans A. H., Lees A. J. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003; 2: 595-604.
8. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders-Text Revision (DSM-IV-TR). Washington, DC: APA; 2000.
9. Lim S. Y., Evans A. H., Miyasaki J. M. Impulse control and related disorders in Parkinson's disease: review. Ann NY Acad Sci 2008; 1142: 85-107.
10. Volkow N. D., O'Brien C. P. Issues for DSM-V: should obesity be included as a brain disorder? Am J Psychiatry 2007; 164: 708-10.
11. Nirenberg M. J., Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006; 21: 524-9.
12. Dittmar H. Compulsive buying-a growing concern? An examination of gender, age, and endorsement of materialistic values as predictors. Br J Psychol 2005; 96: 467-91.
13. Potenza M. N., Voon V., Weintraub D. Drug insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neurol 2007; 3: 664-72.
14. Dagher A., Robbins T. W. Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 2009; 61: 502-10.
15. Evans A. H., Strafella A. P., Weintraub D., Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 2009; 24: 1561-70.
16. Gallagher D. A., O'Sullivan S. S., Evans A. H., Lees A. J., Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007; 22: 1757-63.
17. Voon V., Hassan K., Zurowski M., Duff-Canning S., de Souza M., Fox S. et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006; 66: 1750-2.
18. Giladi N., Weitzman N., Schreiber S., Shabtai H., Peretz C. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 2007; 21: 501-6.
19. Isaias L. U., Siri C., Cilia R., De Gaspari D., Pezzoli G., Antonini A. The relationship between impulsivity and impulse control disorders in Parkinson's disease. Mov Disord 2008; 23: 411-5.
20. Ondo W. G., Lai D. J. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord 2008; 14: 28-32.
21. Singh A., Kandimala G., Dewey R. B., O'Suilleabhain P. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J Clin Neurosci 2007; 14: 1178-81.
22. Voon V., Hassan K., Zurowski M., de Souza M., Thomsen T., Fox S. et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006; 67: 1254-7.
23. Fan W. H., Ding H., Ma J. H., Chan P. Impulse control disorders in Parkinson's disease in a Chinese population. Neurosci Lett 2009; 465: 6-9.
24. Pontone G., Williams J. R., Bassett S. S., Marsh L. Clinical features associated with impulse control disorders in Parkinson's disease. Neurology 2006; 67: 1258-61.
25. Bostwick J. M., Hecksel K. A., Stevens S. R., Bower J. H., Ahlskog J. E. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc 2009; 84: 310-6.
26. Weintraub D., Siderowf A. D., Potenza M. N., Goveas J., Morales K. H., Duda J. E. et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006; 63: 969-73.
27. Lee J. Y., Kim J. M., Kim J. W., Cho J., Lee W. Y., Kim H. J. et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 2009; 16: 202-7.
28. Weintraub D., Koester J., Potenza M., Siderowf A., Stacy M., Voon V. et al. Impulse control disorders in Parkinson's disease: a cross-sectional study of dopaminergic therapy and other clinical features in 3090 patients. Arch Neurol 2010; 67: 589-95.
29. Grosset K. A., Macphee G., Pal G., Stewart D., Watt A., Davie J. et al. Problematic gambling on dopamine agonists: not such a rarity. Mov Disord 2006; 21: 2206-8.
30. Lee J. Y., Lee E. K., Park S. S., Lim J. Y., Kim H. J., Kim J. S. et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov Disord 2009; 24: 1803-10.
31. Crockford D., Quickfall J., Currie S., Furtado S., Suchowersky O., el-Guebaly N. Prevalence of problem and pathological gambling in Parkinson's disease. J Gambl Stud 2008; 24: 411-22.
32. Petry N. M., Stinson F. S., Grant B. F. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2005; 66: 564-74.
33. Sproston K., Erens R., Gambling O. J. Behaviour in Britain: Results from the British Gambling Prevalence Survey. London: National Centre for Social Research; 2000.
34. Bonke J., Borregaard K. The prevalence of problematic gambling behaviour: a Scandinavian comparison. Scand J Public Health 2009; 37: 654-60.
35. Abbott M. W., Volberg R. A., Ronnberg S. Comparing the New Zealand and Swedish national surveys of gambling and problem gambling. J Gambl Stud 2004; 20: 237-58.
36. Avanzi M., Baratti M., Cabrini S., Uber E., Brighetti G., Bonfa F. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 2006; 21: 2068-72.
37. Voon V., Thomsen T., Miyasaki J. M., de Souza M., Shafro A., Fox S. H. et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 2007; 64: 212-6.
38. Imamura A., Geda Y. E., Slowinski J., Wszolek Z. K., Brown L. A., Uitti R. J. Medications used to treat Parkinson's disease and the risk of gambling. Eur J Neurol 2008; 15: 350-4.
39. Santangelo G., Vitale C., Trojano L., Verde F., Grossi D., Barone P. Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. Mov Disord 2009; 24: 899-905.
40. Dodd M. L., Klos K. J., Bower J. H., Geda Y. E., Josephs K. A., Ahlskog J. E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005; 62: 1377-81.
41. Drapier D., Drapier S., Sauleau P., Derkinderen P., Damier P., Allain H. et al. Pathological gambling secondary to dopaminergic therapy in Parkinson's disease. Psychiatry Res 2006; 144: 241-4.
42. Driver-Dunckley E., Samanta J., Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003; 61: 422-3.
43. Klos K. J., Bower J. H., Josephs K. A., Matsumoto J. Y., Ahskog J. E. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005; 11: 381-6.
44. McKeon A., Josephs K. A., Klos K. J., Heeksel K., Bower J. H., Bostwick J. M. et al. Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2007; 13: 516-9.
45. Macphee G. J. A., Copeland C., Stewart D., Grosset K., Grosset D. G. Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study. Mov Disord 2009; 24: 2430-1.
46. Mamikonyan E., Siderowf A. D., Duda J. E., Potenza M. N., Horn S., Stem M. B. et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 2008; 23: 75-80.
47. Anthony J. C., Warner L., Kessler R. C. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994; 2: 244-68.
48. Potenza M. N., Kosten T. R., Rounsaville B. J. Pathological gambling. JAMA 2001; 286: 141-4.
49. Hall W. D. A simplified logic of causal inference. Aust NZ J Psychiatry 1987; 21: 507-13.
50. Merims D., Giladi N. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord 2008; 14: 273-80.
51. Zack M., Poulos C. X. Parallel roles for dopamine in pathological gambling and psychostimulant addiction. Curr Drug Abuse Rev 2009; 2: 11-25.
52. Bodi N., Keri S., Nagy H., Moustafa A., Myers C. E., Daw N. et al. Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain 2009; 132: 2385-95.
53. Evans A. H., Lawrence A. D., Potts J., MacGregor L., Katzenschlager R., Shaw K. et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry 2006; 77: 317-21.
54. Driver-Dunckley E. D., Noble B. N., Hentz J. G., Evidente V. G. H., Caviness J. X., Parish J. et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007; 30: 249-55.
55. Evans A. H. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov Disord 2007; 22: 590-1.
56. Tippmann-Peikert M., Park J. G., Boeve B. F., Shepard J. W., Silber M. H. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007; 68: 301-3.
57. Holman A. J. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J Gambl Stud 2009; 25: 425-31.
58. Holman A. J., Neiman R. A., Ettlinger R. E. Preliminary efficacy of the dopamine agonist, pramipexole, for fibromyalgia: the first, open label, multicenter experience. J Muscoskel Pain 2004; 12: 69-74.
59. Falhammar H., Yarker J. Y. Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust 2009; 190: 97.
60. Cabrini S., Baratti M., Bonfa F., Cabri G., Uber E., Avanzi M. Preliminary evaluation of the DDS-PC inventory: a new tool to assess impulsive-compulsive behaviours associated to dopamine replacement therapy in Parkinson's disease. Neurol Sci 2009; 30: 307-13.
61. Weintraub D., Hoops S., Shea J. A., Lyons K. E., Pahwa R., Driver-Dunckley E. D. et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord 2009; 24: 1461-7.
62. Galpern W. R., Stacy M. Management of impulse control disorders in Parkinson's disease. Curr Treat Options Neurol 2007; 9: 189-97.